In 2016, George A. Scangos earned $5.80M in total compensation at Biogen, including $1.00M salary, $500.00K bonus and $4.00M in stock. Most recently sold 75,000 shares in May 2020. Currently holds stock worth $45.49M. Has donated $2.47M in stock to charitable causes. Led Biogen as CEO for 5 years.
Compensation History
Annual executive compensation data for George A. Scangos, including salary, bonuses, and stock awards.
Year
2016
Total Compensation
$5.80M
Salary
$1.00M
Bonus
$500.00K
Other
$300.00K
Salary
$1.00MBoard Justification
The compensation philosophy aligns with company performance, peer benchmarking, and retention strategies to attract and retain top executive talent.
Bonus
$500.00KBoard Justification
Annual cash bonus based on performance metrics including revenue growth and operating income for the year 2016.
Other Compensation
$300.00KBoard Justification
Other compensation includes retirement contributions and insurance premiums paid by the company.
Restricted Stock
Board Justification
Vested stock options from previous grants that became exercisable in 2016.
Performance Metrics
Performance metrics included revenue growth, operating income, and achievement of strategic goals.
George A. Scangos
Ex-CEO of Biogen
Education
Ph.D. in Microbiology from the University of Massachusetts
Field of Expertise
Healthcare & Life Sciences - Biotechnology
Sector of Economy
Healthcare
Born
January 1, 1953 - 72 years ago
CEO of Biogen for
5 years 11 months (Jul 2010 - Jul 2016)
Previous Experience
President and Chief Executive Officer of Exelixis, Inc.
Holdings
Track George A. Scangos's stock holdings and portfolio value over time.
Total Stock Sold
$54.03M
$23.50M
1,114,894 EXEL shares
$30.53M
118,894 BIIB shares
What if they kept their stock?
If George A. Scangos didn't sell their stock, today they would have:
Extra EXEL1,114,894 shares worth $47.02M and BIIB118,894 shares worth $21.45M.
This is 26.72% and $14.44M more than what they got when they sold the stock.
Charitable Transactions
10,756 shares
BIIB
12,500 shares
EXEL
Recent Charitable Transactions
12,500 shares
EXEL
Dec 27, 2019
Charity
13,950 shares
EXEL
Jan 2, 2019
Charity
10,756 shares
BIIB
Nov 29, 2012
Charity
Insider Trading
George A. Scangos's recent stock transactions, purchases, and sales filed with the SEC.
$1.95M
EXEL at $25.96/share
May 18, 2020
Sale
$3.00M
EXEL at $26.05/share
Apr 23, 2020
Sale
$1.47M
EXEL at $24.45/share
Apr 20, 2020
Sale
$457.75K
EXEL at $18.31/share
Apr 15, 2020
Sale
$430.05K
EXEL at $18.30/share
Apr 7, 2020
Sale
$27.09K
EXEL at $18.06/share
Mar 31, 2020
Sale
$1.04M
EXEL at $20.73/share
Feb 18, 2020
Sale
$502.00K
EXEL at $20.08/share
Feb 11, 2020
Sale
$493.75K
EXEL at $19.75/share
Jan 22, 2020
Sale
$509.75K
EXEL at $20.39/share
Jan 15, 2020
Sale
Rivals
Compare George A. Scangos with competitor CEOs and industry peers.
Daniel O'Day
CEO of Gilead Sciences
2024 Compensation
Stock
$18.79M
Salary
$1.77M
Bonus
$0.00
Other
$1.34M
Total Holdings
$23.48M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Christopher Boerner
CEO of Bristol-Myers Squibb
2023 Compensation
Stock
$0.00
Salary
$1.50M
Bonus
$0.00
Other
$311.64K
Total Holdings
$7.39M
Reshma Kewalramani
CEO of Vertex Pharmaceuticals
2022 Compensation
Stock
$10.64M
Salary
$1.40M
Bonus
$3.78M
Other
$43.06K
Total Holdings
$50.74M
Robert A. Bradway
CEO of Amgen
2024 Compensation
Stock
$0.00
Salary
$1.87M
Bonus
$0.00
Other
$714.33K
Total Holdings
$269.12M
Brett P. Monia, Ph.D.
Founder and CEO of Ionis Pharmaceuticals
2023 Compensation
Stock
$430.00K
Salary
$650.00K
Bonus
$300.00K
Other
$50.00K
Total Holdings
$6.01M